Patent evaluation of US2019338018 (A1) 2019-11-07 (antibody fragments for the treatment of biofilm-related disorders)

References

• Flemming HC, Wingender J, Szewzyk U, et al. Biofilms: an emergent form of bacterial life. Nat Rev Microbiol. 2016;14:563–575.
   PubMed Web of Science ®Google Scholar
• Nur A, Hirota K, Yumoto H, et al. Effects of extracellular DNA and DNA‐binding protein on the development of a Streptococcus intermedius biofilm. J Appl Microbiol. 2013;115:260–270.
   PubMed Web of Science ®Google Scholar
• Devaraj A, Justice SS, Bakaletz LO, et al. DNAIIB proteins play a central role in UPEC biofilm structure. Mol Microbiol. 2015;96:1119–1135.
   PubMed Web of Science ®Google Scholar
• Rocco CJ, Davey ME, Bakaletz LO, et al. Natural antigenic differences in the functionally equivalent extracellular DNABII proteins of bacterial biofilms provide a means for targeted biofilm therapeutics. Mol Oral Microbiol. 2016;32:118–130.
   PubMed Web of Science ®Google Scholar
• Estellés A, Woischnig AK, Liu K, et al. A high-affinity native human antibody disrupts biofilm from Staphylococcus aureus bacteria and potentiates antibiotic efficacy in a mouse implant infection model. Antimicrob Agents Chemother. 2016;60:2292–2301.
   PubMed Web of Science ®Google Scholar
• Novotny LA, Goodman SD, Bakaletz LO. Targeting a bacterial DNABII protein with a chimeric peptide immunogen or humanised monoclonal antibody to prevent or treat recalcitrant biofilm-mediated infections. EBioMedicine. 2020;59:102867.
   PubMed Web of Science ®Google Scholar
• Jiang Y, Geng M, Bai L. Targeting biofilms therapy: current research strategies and development hurdles. Microorganisms. 2020;8:E1222.
   PubMed Web of Science ®Google Scholar
• Wang J, Song M, Pan J, et al. Quercetin impairs Streptococcus pneumoniae biofilm formation by inhibiting sortase A activity. J Cell Mol Med. 2018;22:6228–6237.
   PubMed Web of Science ®Google Scholar
• Ming D, Wang D, Cao F, et al. Kaempferol inhibits the primary attachment phase of biofilm formation in Staphylococcus aureus. Front Microbiol. 2017;8:2263.
   PubMed Web of Science ®Google Scholar
• Zengin G, Menghini L, Di Sotto A, et al. Chromatographic analyses, in vitro biological activities, and cytotoxicity of Cannabis sativa L. essential oil: a multidisciplinary study. Molecules. 2018;23:3266.
   Web of Science ®Google Scholar
• Marinelli L, Fornasari E, Eusepi P, et al. Carvacrol prodrugs as novel antimicrobial agents. Eur J Med Chem. 2019;178:515–529.
   PubMed Web of Science ®Google Scholar
• Zurawski DV, McLendon MK. Monoclonal antibodies as an antibacterial approach against bacterial pathogens. Antibiotics. 2020;9:155.
   Google Scholar
• Nagy CF, Leach TS, Hoffman JH, et al. Pharmacokinetics and tolerability of obiltoxaximab: a report of 5 healthy volunteer studies. Clin Ther 2016;38:2083–2097.
   Google Scholar
• Wilcox MH, Gerding DN, Poxton IR, et al. Bezlotoxumab for prevention of recurrent Clostridium difficile infection. N Engl J Med. 2017;376:305–317.
   PubMed Web of Science ®Google Scholar
• Yang Z, Ramsey J, Hamza T, et al. Mechanisms of protection against Clostridium difficile infection by the monoclonal antitoxin antibodies actoxumab and bezlotoxumab. Infect Immun. 2015;83:822–831.
   PubMed Web of Science ®Google Scholar
• Sun A, Benet LZ. Late-stage failures of monoclonal antibody drugs: a retrospective case study analysis. Pharmacol. 2020;105:145–163.
   PubMed Web of Science ®Google Scholar
• Chan CEZ, Chan AHY, Hanson BJ, et al. The use of antibodies in the treatment of infectious diseases. Singapore Med J. 2009;50:663–673.
   PubMed Web of Science ®Google Scholar
• Lo D A, Waksman G, Remaut H. Bacterial surface appendages as targets for novel antibacterial therapeutics. Future Microbiol. 2014;9:887–900.
   PubMed Web of Science ®Google Scholar
• Vuotto C, Donelli G. Novel treatment strategies for biofilm-based infections. Drugs. 2019;79:1635–1655.
   PubMed Web of Science ®Google Scholar
• Hauser AR, Mecsas J, Moir DT. Beyond antibiotics: new therapeutic approaches for bacterial infections. Clin Infect Dis. 2016;63:89–95.
   PubMed Web of Science ®Google Scholar
• Nelson A, Reichert J. Development trends for therapeutic antibody fragments. Nat Biotechnol. 2009;27:331–337.
   PubMed Web of Science ®Google Scholar
• Holliger P, Hudson PJ. Engineered antibody fragments and the rise of single domains. Nat Biotech. 2005;23:1126–1136.
   PubMed Web of Science ®Google Scholar
• Rodrigo G, Gruvegard M, Van Alstine JM. Antibody fragments and their purification by protein L affinity chromatography. Antibodies. 2015;4:259–277.
   Web of Science ®Google Scholar
• Morellon-Sterling R, El-Siar H, Tavano OL, et al. Ficin: a protease extract with relevance in biotechnology and biocatalysis. Int J Biol Macromol. 2020;162:394–404.
   PubMed Web of Science ®Google Scholar
• Novotny LA, Jurcisek JA, Goodman SD, et al. Monoclonal antibodies against DNA-binding tips of DNABII proteins disrupt biofilms in vitro and induce bacterial clearance in vivo. EbioMedicine. 2016;10:33–44.
   PubMed Web of Science ®Google Scholar
• Mokrzan EM, Dairo KA, Novotny LA, et al. Nontypeable Haemophilus influenzae responds to virus-infected cells with a significant increase in type IV pilus expression. MSphere. 2020;5. DOI:10.1128/mSphere.00384-20
   PubMed Web of Science ®Google Scholar
• Novotny LA, Jurcisek JA, Ward MO, et al. Antibodies against the majority subunit of type IV pili disperse nontypeable Haemophilus influenzae biofilms in a LuxS-dependent manner and confer therapeutic resolution of experimental otitis media. Mol Microbiol. 2015;96:276–292.
   PubMed Web of Science ®Google Scholar
• Ryser S, Tenorio E, Estellés A, et al. Human antibody repertoire frequently includes antibodies to a bacterial biofilm associated protein. PLoS ONE. 2019;14:e0219256.
   PubMed Web of Science ®Google Scholar
• Gollan B, Grabe G, Michaux C, et al. Bacterial persisters and infection: past, present, and progressing. Annu Rev Microbiol. 2019;73:359–385.
   Google Scholar